Interactive Tour and a Whole Lot More
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
On Mar 18, Zacks Investment Research downgraded
Techne Corp. ( TECH - Snapshot Report) to a Zacks Rank #4 (Sell). Why the Downgrade?
Techne witnessed sharp downward estimate revisions after reporting its second-quarter fiscal 2014 (ended Dec 31, 2013) results on Feb 4. Adjusted earnings per share of this MN-based manufacturer of biotechnology and clinical controls products increased 2.4% year over year to 75 cents. However, the results missed the Zacks Consensus Estimate by 5 cents.
On a geographic region basis, sales in Europe, excluding the impact of currency fluctuations, fell 2% as against organic growth of 1.5% witnessed in the previous quarter. On the other hand, European academic sales went down slightly during the second quarter due to relatively flat sales to biotech and pharma customers.
Sales to U.S. academic customers also decreased 4.6% in the quarter. This decline reflects the fact that Techne's customers are facing stressful conditions in the U.S. academic market. This segment is now down to 12% of the company’s consolidated Biotech segment sales.
After considering costs realized upon sale of acquired inventory and amortization of intangible assets, adjusted gross margin dropped 350 basis points to 72.7% in the quarter, due to a change in product mix from higher margin Biotechnology segment sales to Clinical Controls segment sales because of the Bionostics acquisition.
The Zacks Consensus Estimate for 2014 earnings decreased 3.2% to $3.31 per share over the last 60 days. For 2015 as well, most of the estimates were revised downward over the same period, causing the Zacks Consensus Estimate to drop by 3.1% to $3.48. Other Stocks to Consider
In the Medical Instruments space, Cynosure, Inc. ( CYNO - Snapshot Report) , Syneron Medical Ltd. ( ELOS - Snapshot Report) and Cyberonics Inc. are performing well. While Cynosure and Syneron sport a Zacks Rank #1 (Strong Buy), Cyberonics holds a Zacks Rank #2 (Buy).